Product Overview

Anawin 0.25% Inj. (Bupivacaine) is a sterile, water‑soluble local anesthetic formulated for infiltration, nerve block, and epidural anesthesia. The active ingredient, bupivacaine, is an amide‑type anesthetic provided at a 0.25 % concentration (2.5 mg/mL). Each bottle contains 20 mL of solution, packaged in sets of 3, 6, or 9 injections, and is manufactured by Neon Laboratories under strict Good Manufacturing Practice standards. The solution is stored at room temperature, protected from light, and labeled with an expiration date. Its pH is adjusted to 4.0–5.0 to reduce tissue irritation, and the onset of action occurs within 5–10 minutes, with a duration of sensory and motor blockade that can last up to 8 hours depending on dose and injection site. Clinicians appreciate its reliable potency and low systemic toxicity when used according to recommended limits.

What is Anawin 0.25% Inj. (Bupivacaine)

Anawin 0.25% Inj. (Bupivacaine) belongs to the long‑acting amide class of local anesthetics. Its molecular structure includes a piperidine ring linked to a fatty acid chain, granting high lipid solubility and prolonged blockade of voltage‑gated sodium channels in peripheral nerves. The 0.25 % concentration corresponds to 2.5 mg of bupivacaine per milliliter, a dosage that balances efficacy with safety. The product is prescription‑only, regulated by the FDA and listed in the United States Pharmacopeia for adult use. It is indicated for local anesthesia of skin and mucous membranes and for regional nerve blocks requiring a sustained anesthetic effect. Pharmacokinetics show a slow onset, minimal plasma protein binding, and hepatic metabolism with a terminal half‑life exceeding 4 hours in patients with normal liver function.

Uses and Benefits

The therapeutic uses of Anawin 0.25% Inj. (Bupivacaine) include infiltration anesthesia for dermatologic excisions, peripheral nerve blocks for orthopedic procedures, and epidural analgesia during labor. Its long duration permits extended postoperative pain control, reducing the need for supplemental opioids. The medication is also employed in sympathetic and nerve‑root blocks for chronic neuropathic pain management. Benefits stem from predictable onset, extended blockade lasting up to eight hours, and a favorable safety profile when dosing is adhered to. By providing effective regional anesthesia, Anawin facilitates faster patient recovery, shorter hospital stays, and improved satisfaction with surgical or procedural outcomes.

How It Works

Anawin 0.25% Inj. (Bupivacaine) produces anesthesia by reversibly blocking voltage‑gated sodium channels on peripheral nerve membranes, preventing sodium influx and thereby inhibiting action potential propagation. As an amide anesthetic, it is metabolized primarily in the liver by amidases, resulting in a longer metabolic half‑life than ester agents. The drug’s lipid‑soluble nature enables diffusion through nerve sheaths, producing blockade of both sensory and motor fibers. This dual effect yields profound numbness and muscle paralysis that can persist for several hours. Factors such as local tissue vascularity, pH, and inflammatory mediators can modify absorption and distribution, influencing the intensity and duration of the anesthetic effect.

Dosage Guidelines

Dosage of Anawin 0.25% Inj. (Bupivacaine) must be individualized based on procedure, site, patient age, weight, and health status. For infiltration, typical adult doses range from 0.5 to 1 mL per site, not exceeding 150 mg of bupivacaine per operation. Peripheral nerve blocks generally require 10–30 mL, with a maximum single dose of 300 mg in healthy adults. Epidural labor analgesia often uses a 5–10 mL bolus followed by continuous infusion of 5–15 mL per hour, capped at 200 mg in 24 hours. Pediatric dosing is 2 mg per kilogram, with a ceiling of 75 mg per dose. Prior to injection, aspirate to avoid intravascular placement, and monitor vital signs throughout the procedure. Discontinue administration at the first sign of systemic toxicity.

Side Effects

Adverse reactions to Anawin 0.25% Inj. (Bupivacaine) are usually mild and self‑limiting. Common local effects include transient pain, bruising, or swelling at the injection site. Systemic side effects may present as dizziness, light‑headedness, or a metallic taste. Rare but serious complications encompass cardiac arrhythmias, myocardial infarction, and seizures, particularly if the drug enters the bloodstream. Allergic responses, though uncommon, can manifest as urticaria or, in severe cases, anaphylactic shock. To reduce toxicity risk, clinicians should adhere to recommended dose limits, employ proper aspiration, and monitor patients with cardiac or hepatic impairment closely. In the event of suspected overdose, supportive measures include airway protection, ventilation assistance, and, when indicated, lipid‑emulsion therapy.

Warnings and Precautions

Anawin 0.25% Inj. (Bupivacaine) is contraindicated in patients with known hypersensitivity to bupivacaine or any formulation component. Caution is required in individuals with severe cardiac conduction disease, hepatic dysfunction, or those receiving other amide anesthetics, as drug interactions may increase toxicity risk. Pregnant or lactating women should receive the medication only when the expected benefit justifies the risk; dosing should be minimized and the lowest effective amount chosen, after consulting a healthcare professional. The solution must not be administered intravenously; therefore, aspiration and injection into well‑vascularized tissue are mandatory. Store the product in a cool, dry place away from light, and inspect for particulates or discoloration before use. Keep out of children’s reach and retain the original packaging to prevent accidental ingestion.

Frequently Asked Questions

1. Question: What is the maximum single dose of Anawin? Answer: For adults, do not exceed 300 mg of bupivacaine in a single injection; pediatric maximum is 2 mg/kg, not exceeding 75 mg per dose. U.S. Food and Drug Administration
2. Question: How long does the anesthetic effect last? Answer: The sensory and motor block can persist up to 8 hours, depending on dose and injection site; longer duration is possible with larger volumes. National Institutes of Health
3. Question: Can Anawin be used in children? Answer: Yes, children can receive Anawin when dosed at 2 mg per kilogram of body weight, with a ceiling of 75 mg per dose, under close medical supervision. MedlinePlus
4. Question: Is it safe to use during pregnancy? Answer: Anawin may be used in pregnancy only when the expected benefit justifies the risk; dosing should be minimized and the lowest effective amount chosen, after consulting a healthcare professional. U.S. Food and Drug Administration
5. Question: What should be done if a patient experiences seizures after injection? Answer: Immediately stop administration, secure the airway, provide ventilatory support, and consider lipid‑emulsion therapy; seek emergency medical assistance. U.S. Food and Drug Administration

Related Products

• Vanking 1000 Infusion (Vancomycin)
• Intacaine 2% Gel 30g (Lidocaine)
• Xylocaine Jelly (Lidocaine)
• Xylocaine Ointment (Lidocaine)
• Lox Heavy Injection (Lidocaine)
• Vasocon Injection (Adrenaline (Epinephrine))
• Hodpro 50mg (Procarbazine)
• Anawin Injection (Bupivacaine)
• Anawin 0.5% inj. (Bupivacaine)
• Anawin Heavy 5 mg Injection (Bupivacaine)
• LOX 2% Inj (Lidocaine or lignocaine)
• Lox 10% Spray (Lidocaine or lignocaine)